Skin thermal injury caused by burns or explosives is the main cause of morbidity and death, and it is also a great burden on the current global health care system; The severity of the injury is mainly due to the potentially fatal sepsis caused by multi drug resistant (MDR) bacteria (such as Pseudomonas aeruginosa, mdr-pa). Recently, in a research report entitled Ab569, a novel, topical bacterial gel formulation, kills Pseudomonas aeruginosa and promotes wound healing in a murine model of burn wound infection published in the international journal infection and immunity, scientists from the University of Cincinnati School of medicine and other institutions found through research, The use of a topical drug called ab569, the combination of acidified nitrite and EDTA, may kill antibiotic resistant bacteria and enhance wound healing of various burn types.

picture source：Pixabay/CC0 Public Domain

Ab569 was patented in the United States by Daniel Hassett, a researcher at the University of California in 2018. He found that ab569 could kill almost all tested pathogens, and no acquired drug resistance was observed; According to CDC data in the United States, bacteria including mdr-pa may be the most serious pathogen that can show multiple and enhanced virulence characteristics.

Researchers often call multidrug-resistant bacteria superbacteria, which is a global human health problem emerging in recent years; At present, researchers urgently need to develop new and effective antibiotics to prevent, treat, remove and cure this complex wound caused by the terrible pathogen (mdr-pa) carried by burn patients, and the severity of the injury is mainly due to the potentially fatal sepsis caused by mdr-pa.

The researchers found that ab569 can actually play a synergistic role to kill all pathogens in human burn wounds in vitro. Ab569 can not only kill pathogens, but also enhance the wound healing process of patients. At the same time, the local application of ab569 can also increase the anti-inflammatory mediator function of the body, so as to help improve the recovery of epidermal function, so as to promote wound healing more quickly and effectively.

picture source: https://journals.asm.org/doi/10.1128/IAI.00336-21

Ab569 was initially considered as a potential treatment for a variety of antibiotic resistant pathogens, which can cause pulmonary infection in patients with cystic fibrosis and chronic obstructive pulmonary disease (COPD) and a variety of other opportunistic infections; In addition to resolving COPD and cystic fibrosis, AB569 can also effectively resolve infections associated with severe burns, urinary tract diseases, endocarditis and diabetes.

In summary, this study provides solid evidence that AB569 can be used for severe skin injury in local treatment, including wound infection, burns, explosions and possible diabetes infection, and helps to alleviate the economic burden caused by multi drug resistant bacteria to the global health care system.